Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to four non-executive employees under its 2018 Equity Inducement Plan. The independent Compensation Committee approved stock options for an aggregate 19,436 shares and 6,186 RSUs on August 3, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $94.93, equal to Spyre’s August 3, 2026 closing share price. Options vest 25% on the first employment anniversary and monthly thereafter over four years, while RSUs vest in four equal annual installments on specified quarterly dates, in each case subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The disclosure is an award grant rather than a completed share issuance: Spyre Therapeutics approved options covering 19,436 shares and 6,186 RSUs for four employees on August 3, 2026, with vesting tied to continued service, so it does not establish immediate dilution.
Market Context
Historical records include comparable inducement-award releases under news_id 1077720 and news_id 10...
Analysis
Historical records include comparable inducement-award releases under news_id 1077720 and news_id 1067578, while current insider context was Net Selling. The effective S-3ASR shelf and moderate short positioning were additional risk factors to monitor.
Key Figures
Stock options:19,436 sharesRestricted stock units:6,186 RSUsEmployees receiving awards:4 employees+5 more
8 metrics
Stock options19,436 sharesInducement awards to four non-executive employees
Restricted stock units6,186 RSUsInducement awards to four non-executive employees
Enrollment completed across all SKYWAY basket-trial sub-studies.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Comparable inducement-award announcements produced mixed 24-hour reactions, while positive clinical and enrollment updates generally aligned with positive reactions.
"approved the grant of stock options ... as equity inducement awards"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
restricted stock unitsfinancial
"and 6,186 restricted stock units (“RSUs”) to four non-executive employees"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 19,436 shares of common stock of Spyre and 6,186 restricted stock units (“RSUs”) to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on August 3, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $94.93, the closing price per share of Spyre's common stock as reported by Nasdaq on August 3, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
What equity inducement awards did Spyre Therapeutics (NASDAQ: SYRE) grant on August 3, 2026?
Spyre Therapeutics granted stock options for 19,436 shares and 6,186 restricted stock units as inducement awards. According to Spyre Therapeutics, these grants were approved by the Compensation Committee under the 2018 Equity Inducement Plan for four non-executive employees.
What is the exercise price and term of the new Spyre Therapeutics (SYRE) stock options?
The new Spyre Therapeutics stock options have a 10-year term and an exercise price of $94.93 per share. According to Spyre Therapeutics, this price equals the closing price of its common stock on Nasdaq on August 3, 2026.
How do the Spyre Therapeutics (SYRE) inducement stock options vest for the new employees?
The inducement stock options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter over the remaining three years. According to Spyre Therapeutics, vesting is conditioned on continuous service through each applicable vesting date.
How do the new Spyre Therapeutics (SYRE) RSUs vest for the four employees?
The RSUs vest in four equal 25% installments on each anniversary of the next February 15, May 15, August 15, or November 15 after the start date. According to Spyre Therapeutics, vesting requires ongoing employment through each vesting date.
Under which plan were the Spyre Therapeutics (SYRE) inducement awards granted and why?
The inducement stock options and RSUs were granted under the Spyre Therapeutics 2018 Equity Inducement Plan. According to Spyre Therapeutics, the awards were material to each employee’s acceptance of employment and comply with Nasdaq Listing Rule 5635(c)(4).
How many employees received the new Spyre Therapeutics (SYRE) inducement equity awards?
Four non-executive employees received the inducement equity awards from Spyre Therapeutics. According to Spyre Therapeutics, these employees were granted an aggregate of 19,436 stock options and 6,186 RSUs as part of their employment offers.
